Abbott Medical is the FDA applicant named in filings for spinal cord and deep brain stimulation hardware, defibrillation leads and accessories. The linked entries describe supplier and material changes and name the UltiSynq and SurGrip components, with separate product descriptions in Abbott’s published technical materials.
Abbott Medical is the FDA applicant named in filings for spinal cord and deep brain stimulation hardware, defibrillation leads and accessories. The linked entries describe supplier and material changes and name the UltiSynq and SurGrip components, with separate product descriptions in Abbott’s published technical materials.
ABBOTT MEDICAL is the applicant named in the FDA filings discussed here. The documented products include implantable pulse generators and their chargers for spinal cord stimulation and deep brain stimulation, plus the UltiSynq defibrillation lead and SurGrip suture sleeve accessory. The submission identifiers keep each product and change separate: several filings belong to existing PMA families, and each has its own recorded decision date and scope. [1][2][3][4][5]
Neuromodulation supplements decided in October 2026
The largest cluster in the public documents concerns spinal cord stimulation and deep brain stimulation hardware. P010032/S264 covers a Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger, received 2026-09-30 and decided 2026-10-30 under a 30-Day Notice, with the applicant's stated scope being qualification of an alternate MOSFET electronic component and supplier [2]. P010032/S266 covers the SCS IPG itself, received the same day and decided the same day, with a stated change from animal-derived to non-animal-derived EBS lubricant in TPU resin production for the Bluetooth low energy antenna [5].
On the DBS side, P140009/S144 covers the Deep Brain Stimulation (DBS) IPG with the same lubricant change and antenna scope, received 2026-09-30 and decided 2026-10-30 [3]. P140009/S142 covers the DBS IPG Charger with the alternate MOSFET qualification, same dates [4]. All four carry the Neurology advisory committee and product codes LGW or MHY. The stated reasons concern manufacturing processes and component suppliers. [2][3][4][5]
UltiSynq defibrillation lead approval
P950022/S153 covers the UltiSynq Defibrillation lead and SurGrip Suture Sleeve Accessory, product code LWS, Cardiovascular committee. The FDA record shows a Normal 180 Day Track supplement received 2026-04-23 and approved 2026-11-05, with supplement reason Change Design/Components/Specifications/Material [1]. The approval statement in the record names both the lead and the accessory [1].
Abbott’s product page describes UltiSynq’s ICD lead coil design. Its product page and technical PDF supply a manufacturer description of the lead; the FDA entry records the particular supplement and names the accessory. Those documents answer different research questions, so the product page should not replace the exact regulatory filing. [1][7][10]
What the filing record does and does not establish
The linked filings record submission and decision dates, supplement types, product codes, advisory committees and applicant-stated changes. The 49-record count is an as-of snapshot of filings linked by MedtechLedger and retrieved on November 20, 2026. It does not represent total company sales, the full device portfolio, market share or a measure of safety performance.
For research on these changes, begin with the exact supplement number. The charger filings identify a MOSFET component and supplier, while the generator filings concern an antenna manufacturing material. The charger and generator entries identify different changed items within their respective named product families. [2][3][4][5]
Identity and attribution boundaries
The FDA application field provides the legal applicant name for each cited submission. ABBOTT MEDICAL is the name used in these records. Sylmar and Plano addresses are recorded as filing contact details and are not labeled as corporate headquarters in these filings. Product descriptions for UltiSynq originate with Abbott’s cardiovascular product page and PDF. [1][2][7][10]
MedtechLedger currently links 288 FDA records to the applicant name ABBOTT MEDICAL. The collection includes 8 510(k) clearances. It includes 15 original PMA approvals. 111 entries are PMA supplements. 154 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 10, 1996 to Nov 5, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code DSQ appears in 39 of the 288 linked filings. The collection spans 33 FDA product codes and 32 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P160054, with 29 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 45 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 15900 Valley View Ct., Sylmar, CA, 91335. Recorded on P950022/S153, decision dated Nov 5, 2026.
FDA record P950022/S153 is an approved supplement to PMA P950022 for Abbott Medical, not a new PMA. The supplied record states approval for the UltiSynq™ Defibrillation lead and the SurGrip™ Suture Sleeve Accessory, so the action is tied to those named components rather than to a new device system scope.
The supplement type is “Normal 180 Day Track,” and the listed reason is “Change Design/Components/Specifications/Material.” The source does not describe the exact design, component, specification, or material changes, so the specific modified item beyond those field labels is not stated in the supplied record.
FDA approval-order wording
approval for UltiSynq Defibrillation lead and the SurGrip Suture Sleeve Accessory
P010032/S264 records decision OK30 dated October 30, 2026 for Abbott Medical's Spinal Cord Stimulation Implantable Pulse Generator Charger. The 30-Day Notice identifies qualification of an alternate metal-oxide-semiconductor field-effect transistor, or MOSFET, electronic component and supplier. FDA assigns the entry to process changes involving a manufacturer, sterilizer, packager or supplier.
The recorded change is the alternate electronic part and its supplier qualification. The statement does not name the supplier, identify the MOSFET part number, list electrical specifications, or disclose qualification test results. The parent application number is P010032 and the product code is LGW. This notice therefore documents a component-sourcing change associated with the charger, while the engineering comparison with the previously used part remains absent from the public entry.
FDA approval-order wording
qualification of an alternate MetalOxideSemiconductor Field-Effect Transistor (MOSFET) electronic component and supplier
FDA records this as supplement P140009/S144 to the original PMA P140009 for Abbott Medical’s Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG). The entry is a 30-Day Notice for a process change, not a new PMA approval or a statement of clinical performance.
The source names the changed item as an animal-derived to non-animal derived EBS lubricant used in TPU resin production for the BLE antenna manufacturing process. The stated scope is limited to the BLE antenna in the IPG for the bundled DBS and SCS devices; the record does not provide the technical reason for the change or any new safety or effectiveness data.
FDA approval-order wording
animal-derived to non-animal derived EBS [Ethylene Bis-stearamide] lubricant to be used in TPU [thermoplastic polyurethane] resin production for the BLE [Bluetooth low energy] antenna manufacturing process. This applies specifically to the BLE antenna used in the IPG [implantable pulse generator] for either bundled device; DBS [Deep Brain Stimulator] and SCS [Spinal cord Stimulator]
The FDA recorded decision OK30 on 2026-10-30 for P140009/S142, a 30-Day Notice supplement to Abbott Medical's Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The stated scope is qualification of an alternate Metal-Oxide-Semiconductor Field-Effect Transistor (MOSFET) electronic component and supplier.
This action concerns a component and supplier change within the existing PMA, not a new approval of the whole system. The device category is an implanted electrical stimulator for parkinsonian tremor, specialty Neurology, product code MHY. The source record does not include the supplement documents, so the specific MOSFET, supplier identity, qualification testing and any conditions of the decision remain unknown.
The decision code OK30 is not expanded in the source, and no clinical or labeling conclusions follow from this record.
FDA approval-order wording
qualification of an alternate MetalOxideSemiconductor Field-Effect Transistor (MOSFET) electronic component and supplier
FDA posted a 30-day notice for PMA supplement P010032/S266, dated 2026-10-30, with decision OK30. The supplement reason is a process change involving manufacturer, sterilizer, packager, or supplier. The stated change is from an animal-derived to a non-animal-derived EBS lubricant used in TPU resin production for the BLE antenna manufacturing process.
The statement specifies that this applies to the BLE antenna used in the implantable pulse generator for either bundled device: the deep brain stimulator and the spinal cord stimulator. The device category is a totally implanted spinal-cord stimulator for pain relief, product code LGW, with Abbott Medical as the applicant. The source does not state whether the change affects device safety or performance.
FDA approval-order wording
animal-derived to non-animal derived EBS [Ethylene Bis-stearamide] lubricant to be used in TPU [thermoplastic polyurethane] resin production for the BLE [Bluetooth low energy] antenna manufacturing process. This applies specifically to the BLE antenna used in the IPG [implantable pulse generator] for either bundled device; DBS [Deep Brain Stimulator] and SCS [Spinal cord Stimulator]
Oct 30, 2026 · 30-Day Notice
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
RECALL COVERAGE
Recalls linked to this firm
MedtechLedger links 5 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 5 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.
Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.
Source information
Source updated Nov 11, 2026. Retrieved Nov 21, 2026.